Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine + CAG + venetoclax for elderly or unfit AML
ChiCTR2200059694Phase 3Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by West China Hospital of Sichuan University. Primary endpoint: complete remission rate. Started Jun 2022; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200059694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059694.